BVI Medical raises $1bn as it targets larger global footprint
Ophthalmology specialist BVI Medical has completed a $1bn capital raise as it positions itself to challenge the might of seasoned eye-surgery device suppliers such as Alcon and Johnson & Johnson (J&J).
US-headquartered BVI executed the strategic raise in partnership with TPG, a private equity company with assets under management totalling $246bn. The investment represents a doubling-down from TPG, which acquired BVI from RoundTable Healthcare Partners for an undisclosed amount in 2016.
BVI offers a range of ophthalmic devices, ranging from cryosurgery and cataract surgery systems to intraocular lenses and instruments for retinal surgery. The company's primary manufacturing facilities are based in the US, though it plans to expand its global footprint based on the big-dollar contribution from TPG.
'This investment marks a pivotal moment for BVI as we scale our capabilities to meet the rising demand for advanced ophthalmic solutions,' said BVI CEO Shervin Korangy.
BVI currently supplies devices to surgical teams in more than 90 countries, either directly or through distribution channels. It is a privately held company, so no financials are available publicly from last year or insights on which regions generated the most revenue.
Aside from pointing to new product launches and widening the reach of its customer base, the company did not disclose detailed plans of where the investment will be funnelled. BVI stated only that the investment refinances existing debt and adds new equity.
BVI has been ramping up its global expansion efforts and boosted its intraocular lens manufacturing capabilities in Europe in 2023. The new facility in Belgium opened in July 2023, enhancing the yield and efficiency of its intraocular lens business. In the same year, it also expanded its presence in Spain and Portugal with the acquisition of ophthalmic surgery device supplier Medical Mix. Within its intraocular business, BVI also launched new products such as its Serenity line intraocular lenses.
The ophthalmic device market was estimated to be worth $7.8bn in 2024 and is forecast to reach $9.8bn by 2033, fuelled by increasing prevalence of eye diseases among ageing global populations. Analysis by GlobalData places Alcon, previously a Novartis subsidiary until its spin-off in 2019, as the company with the largest global market share. J&J Vision and Zeiss take second and third spots, respectively, as per the market analysis. Zeiss recently made its own financial play, acquiring Dutch Ophthalmic Research Center for $1.07bn last year.
"BVI Medical raises $1bn as it targets larger global footprint" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Amazon.com (NasdaqGS:AMZN) Expands AWS Presence With US$5 Billion Data Center Investment In Taiwan
recently announced the launch of its AWS Asia Pacific (Taipei) Region, highlighting a $5 billion investment in data center infrastructure. This expansion, coupled with a $10 billion investment in North Carolina to bolster AI and cloud computing capabilities, underscores Amazon's commitment to innovation and business growth. These significant developments align with Amazon's overall strategic objectives and may enhance its market position. The company's share price rose 13% over the past month, coinciding with the market's general upward trend, which experienced a 13% rise over the past year across the broader market. Buy, Hold or Sell View our complete analysis and fair value estimate and you decide. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent developments regarding Amazon's investments in the AWS Asia Pacific (Taipei) Region and North Carolina can significantly influence the company's operational strategy, furthering its drive towards AI and cloud computing capabilities. These initiatives are expected to enhance revenue streams, aligning with the company's narrative of optimizing efficiency through advanced technologies. Over the three-year timeframe, Amazon's total shareholder return, inclusive of share price and dividends, achieved a 94.77% increase. Within the past year, Amazon's share price rise of 13% outpaced the broader market's 12.6% gain, reflecting robust performance despite prevailing industry challenges. In light of Amazon's stated commitments, analysts have projected revenue growth of 8.9% per annum, bolstered by both traditional and AI-driven cloud services. Earnings prospects are anticipated to rise to US$103.6 billion by 2028, up from US$65.94 billion today. While these expansions present opportunities for substantial revenue increases, the pressure from infrastructure investments must be carefully managed to sustain growth expectations. With a current share price of US$185.01, the 22.7% higher analyst price target of US$239.33 illustrates an optimistic market consensus. However, investors are advised to consider both market risks and the variations in analyst predictions when evaluating Amazon's future prospects. Unlock comprehensive insights into our analysis of stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:AMZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Netflix (NasdaqGS:NFLX) Enters Creative Partnership With India's Ekta Kapoor For New Series
Netflix recently announced a long-term creative collaboration with Telefilms Ltd., led by renowned Indian creator Ekta Kapoor, aimed at developing a variety of projects for streaming audiences. Over the last quarter, Netflix's stock price increased by 39%, significantly outperforming the broader market, which rose by 2%. The company's remarkable quarterly earnings with improved sales and profits likely contributed to this rise. Additionally, its ongoing share buyback program further bolstered investor confidence. While these developments supported its upward trajectory, Netflix's stock rise was in stark contrast to the relatively modest market increase, highlighting its exceptional performance. Buy, Hold or Sell Netflix? View our complete analysis and fair value estimate and you decide. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Netflix's recent collaboration with Telefilms Ltd. could enhance its content portfolio, particularly by tapping into the growing Indian market. This agreement is likely to support Netflix's goal of expanding its global content strategy and potentially boost revenue and profit margins. Such initiatives might align with analysts' expectations of a 12% annual revenue growth over the next few years. Over the past three years, Netflix's total shareholder return was very large, underscoring its robust long-term performance. This period has seen significant outperformance relative to shorter-term gains when compared to the broader market's annual increase of 12.6% over the last year. In the same one-year period, Netflix's stock rose more than twice as much as the broader market, highlighting its impressive performance against industry benchmarks. The forecasted increase in ad revenue and gaming expansion could significantly drive future earnings, potentially increasing Netflix's earnings forecast from US$9.27 billion to as high as US$16.1 billion by 2028. However, these ambitious goals come amidst economic risks and competition, as highlighted in the narrative. Recent price movements see Netflix's stock trading at US$1137.69, with a modest 3.7% discount to the consensus price target of US$1096.58. This suggests that analysts, on average, consider Netflix fairly valued, factoring in the company's growth prospects and risks. Gain insights into Netflix's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:NFLX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Bloomberg
9 hours ago
- Bloomberg
China Approves Some Exports of Rare Earths Ahead of US Talks
Beijing says it granted approval to some applications for the export of rare earths, a move that could ease tensions before trade negotiations between the US and China next week. The Chinese commerce ministry confirmed the approval of the applications without specifying which countries or industries were covered, even as it noted growing demand for the minerals in robotics and electric vehicles. The ministry will continue to review and approve compliant export applications, according to a statement on Saturday.
